Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. GreenBank Capital Inc.
  6. News
  7. Summary
    GRNBF   CA3935762029

GREENBANK CAPITAL INC.

(GRNBF)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : GreenBank Capital Inc.: GreenBank Capital to Acquire Significant Stake in Globally Important COVID-Killer

05/04/2021 | 06:01am EDT
DGAP-News: GreenBank Capital Inc. / Key word(s): Acquisition 
GreenBank Capital Inc.: GreenBank Capital to Acquire Significant Stake in Globally Important COVID-Killer 
2021-05-04 / 12:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
GreenBank Capital to Acquire Significant Stake in Globally Important COVID-Killer 
 
This news release is not for distribution or dissemination in the United States of America 
TORONTO, ON / ACCESSWIRE / May 4, 2021 / GreenBank Capital Inc. (CSE:GBC)(OTC PINK:GRNBF)(FRA:2TL) ("GreenBank" or "the 
Company") is exceptionally pleased to announce that it has reached agreement to acquire a significant stake in 
CodiKoat, the UK-based producer of a patent-pending destroyer of the COVID-19 virus ("Covid") and any of its mutations, 
together with any other existing and novel viruses that could emerge in the future. 
Any surface treated with CodiKoat products instantly becomes a Covid-destroying medium. From touchscreen terminals, to 
hospital surfaces and supermarket trolley handles, as well as masks and gloves, the CodiKoat application instantly 
destroys Covid and any other viruses on contact. 
CodiKoat are also optimistic that deploying air filters coated with CodiKoat's revolutionary and patent-pending 
products could turn air conditioners or air filtration units into Covid-destroying air purifiers, thereby dramatically 
enhancing the safety of indoor spaces. If they are successful in applying the technology in this way, CodiKoat will 
offer a more effective and lower cost alternative to other air filtration technologies including HEPA filters. 
Whilst vaccines are beginning to provide significant protection against current strains of Covid in a number of 
countries, it is expected by many that existing and future mutations of the virus, as well as the emergence of other 
novel viruses, will continue to pose significant threats to world health. It remains likely that, if unchecked, such 
mutations or novel viruses would have the capacity to cause large scale deaths and a return to severely damaging 
economic lockdowns. CodiKoat's innovative, virus-destroying technology is capable of radically enhancing the fight 
against such threats. CodiKoat management believe that, in time, there may well be international regulatory 
requirements for products and surfaces regularly coming into contact with people to be coated with the type of products 
that CodiKoat has already developed and is also developing. 
CodiKoat's technology works by using surface-functionalised nanostructures to inactivate viruses instantly. It also the 
same effect on fungi and bacteria. CodiKoat have developed a high-precision coating process to apply their product in a 
highly controllable and uniform manner. This provides a strong chemistry of nanostructures with the surface, which 
leads to high durability, lasting for the whole product lifetime. CodiKoat technology can coat any surface - be it hard 
or soft, rough or smooth, curved or flat - with nanoparticles of any composition and size. CodiKoat materials can be 
easily tuned at an atomic scale and integrated into existing manufacturing lines for any product. 
Existing technologies generally use silver or copper-based particles to kill viruses and bacteria. However, these 
materials can take hours to produce any antiviral/antimicrobial effect, are significantly less effective than CodiKoat, 
and last only a limited time (typically 30-60 days) whereas CodiKoat's antiviral, antifungal and antibacterial effects 
are permanent. CodiKoat's unique solution uses weak electric current to alter the surface charge characteristic of the 
virus particles. This modification in surface charge destabilises the electrokinetic properties of the viruses and 
facilitates aggregation of these particles. The aggregated viral particles lose their ability to enter host cells and 
infect them. This mechanism happens in a short time scale (< 10 seconds) producing a fast-acting inactivation of viral 
particles. 
CodiKoat's technology have been developed in association with the University of Cambridge, Oxford Innovation and the 
Cambridge Centre, partly with grant funding provided by the United Kingdom government's Innovate UK Fund. 
The initial deployments of the technology will be in face masks (CodiKoat is working with the UK's largest respirator 
producer, Cardiff-based Hardshell UK) and adhesive acetate film which can be applied to any number of surfaces to give 
life-long protection. The company's commercial partners for the acetate film product are BDK Industrial Products 
Limited, who describe themselves as one of Europe's leading adhesive tape producers and have a division dedicated to 
producing products for the medical market. 
CodiKoat products are currently being trialled in offices as well as with a leading chain of UK Care Homes, ATM 
provider, Cash On The Move, and the Royal Opera House, 
The fact that, as well as destroying viruses on contact, CodiKoat products can also permanently protect surfaces 
against all bacteria, offers the possibility of vastly improving sanitation in hospitals and dining areas, as well as 
eradicating the kind of germs that are found in public conveniences and surrounding areas. In the US alone, 
hospital-acquired infections are thought to cost the US economy upwards of USUSD30bn a year - and that was before the 
emergence of Covid. 
The UK's secretary of state for Health has recognised the potential impact that CodiKoat could have in that country's 
National Health Service and after learning about what the technology could do, commented "That's amazing, I could see 
the benefit of this immediately, including within the NHS." (https://www.cambridgeindependent.co.uk/business/ 
anti-viral-coating-could-end-surface-transmission-of-covid-9159003/). 
The CodiKoat team include: 
Dr Reza Saberi. Reza holds a PhD in physics from the University of Cambridge and has over 12 years' experience in 
materials development processes and holds a portfolio of patents on coating techniques. 
Dr Matin Mohseni. Matin is a biomedical scientist and engineer. He holds a PhD in development and targeting of metal 
oxide nanoparticles from UCL and has several publications in related scientific journals. 
Dr Payam Nahavandi. Payam is a biomedical engineer and holds a PhD in Medical Imaging from UCL. He has managed numerous 
multidisciplinary projects during his career, leading to several high impact publications. 
Mr Raj Sharma. Raj is a serial entrepreneur and has been involved as a Co-Founder, Investor and Director in a variety 
of successful start-ups in a variety of fields including tech, medical, automotive and food and drink. 
Terms of investment 
GreenBank has reached agreement to acquire up to an initial 15% of CodiKoat. 
The Company will pay GBP540,000 (CUSD930,000) for 5% of CodiKoat's fully diluted share capital and has been granted a 
twelve-month option to acquire a further 10% of CodiKoat at the lower of a GBP100m (CUSD172m) valuation or the price at 
which CodiKoat raises any further funding. 
In addition, CodiKoat have indicated that they would like to work with GreenBank in shaping the company's strategy 
going forward, which may include a listing on the Canadian Securities Exchange with GreenBank's help. 
Commenting on the investment in CodiKoat and the developing relationship, David Lonsdale, CEO of GreenBank said, 
"CodiKoat have developed a Covid destroying product line with hugely positive ramifications for the entire world, as we 
see the continuing devastating effects of Covid in India and elsewhere. The prevalence of Covid mutations is providing 
an ever-present threat of return to lockdown should those mutations successfully evade vaccine defences, and CodiKoat 
have developed a Covid destroying technology that has the potential to markedly reduce the incidence of Covid, Covid 
mutations and other life threatening novel viruses in public spaces. We believe CodiKoat has the potential to help 
radically improve the chances of normal life resuming on a more stable and permanent basis throughout the world, and we 
are therefore thrilled to play our part in helping CodiKoat fulfil its potential to significantly enhance the safety 
and wellbeing of so many people". 
Raj Sharma of CodiKoat said "We are delighted to be working with GreenBank Capital, the next generation Merchant Bank, 
as we bring to market our crucial life-saving suite of products. Time is of the essence in bringing our products to 
market and GreenBank have shown themselves to be nimble, innovative and professional and we are really excited to be 
moving towards listing our company at the earliest opportunity in order to help maximise our scale of operations ." 
About GreenBank 
GreenBank is a next generation merchant banking business that has a flexible low-cost overhead structure designed to 
maximize profitability. Our management are based in Toronto, Dallas, New York and London and are used to working across 
borders remotely. Our model of remote working, dynamic space and flexible contracts -rather than expensive offices, and 
large fixed costs - establishes GreenBank as a global merchant bank for the future, both during and after COVID19. 
GreenBank is listed on the Canadian Securities Exchange, the Frankfurt Boerse and on the OTC Markets in the USA. 
(Trading symbols CSE: GBC and FRA: 2TL and OTCMKTS: GRNBF). GreenBank invests in undervalued exponential growth 
companies focused on building consistent capital appreciation for its shareholders. 
For details of our "6 Key Drivers of Value" please see our latest Investor Presentation: 
https://greenbankcapitalinc.com/wp-content/uploads/2020/11/03.11.20_Greenbank-Deck-compressed.pdf 
For more information please visit our website www.GreenBankCapitalInc.com or contact 
Mark Wettreich at +1 (214) 202-4353 or by email Mark@GreenBankCapitalinc.com 
SOURCE: GreenBank Capital Inc. 

(MORE TO FOLLOW) Dow Jones Newswires

May 04, 2021 06:00 ET (10:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
GREENBANK CAPITAL INC. -5.99% 1.443 Delayed Quote.643.81%
SILVER 0.62% 27.4331 Delayed Quote.3.53%
All news about GREENBANK CAPITAL INC.
05/04PRESS RELEASE  : GreenBank Capital Inc.: GreenBank -2-
DJ
05/04PRESS RELEASE  : GreenBank Capital Inc.: GreenBank Capital to Acquire Significan..
DJ
05/04GREENBANK CAPITAL INC. : GreenBank Capital to Acquire Significant Stake in Globa..
EQ
04/19GREENBANK CAPITAL  : announces that BBC subsidiary, UKTV, is investing alongside..
AQ
04/12GREENBANK CAPITAL  : Portfolio Company Staminier Raises C$17m, and Completes Sub..
AQ
04/08GREENBANK CAPITAL  : completes purchase of significant stake in Flex Capital, a ..
AQ
04/06GREENBANK CAPITAL  : Helps Pharmakure, The Pioneer of An Important And potential..
AQ
04/01GREENBANK CAPITAL INC.  : Closes $4,458,859 Private Placement Financing
AQ
03/30GREENBANK CAPITAL TO PRESENT AT THE : 30am Est, On March 31, 2021
AQ
03/29GREENBANK CAPITAL  : Successfully Raises $4,454,358 in Private Placement
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -1,29 M -1,06 M -1,06 M
Net Debt 2020 0,74 M 0,61 M 0,61 M
P/E ratio 2020 -7,00x
Yield 2020 -
Capitalization 105 M 86,4 M 86,4 M
EV / Sales 2019 358x
EV / Sales 2020 -
Nbr of Employees -
Free-Float 45,1%
Chart GREENBANK CAPITAL INC.
Duration : Period :
GreenBank Capital Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
David M. Lonsdale President, Chief Executive Officer & Director
Miles A. Nagamatsu Chief Financial Officer
Mark Wettreich Executive Chairman, Secretary & Vice President
Peter D. Wanner Independent Non-Executive Director
Alex Wettreich Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GREENBANK CAPITAL INC.643.81%86
MORGAN STANLEY26.70%163 174
THE CHARLES SCHWAB CORPORATION35.28%135 263
THE GOLDMAN SACHS GROUP, INC.40.64%131 661
CITIC SECURITIES COMPANY LIMITED-20.27%44 507
EAST MONEY INFORMATION CO.,LTD.-2.61%40 420